Singapore
· Delayed Price · Currency is SGD Pharmesis International Statistics
Total Valuation
Pharmesis International has a market cap or net worth of SGD 14.74 million. The enterprise value is 17.63 million.
| Market Cap | 14.74M |
| Enterprise Value | 17.63M |
Important Dates
The next estimated earnings date is Friday, November 8, 2024.
| Earnings Date | Nov 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Pharmesis International has 31.70 million shares outstanding. The number of shares has increased by 15.38% in one year.
| Shares Outstanding | 31.70M |
| Shares Change (YoY) | +15.38% |
| Shares Change (QoQ) | +1.41% |
| Owned by Insiders (%) | 48.09% |
| Owned by Institutions (%) | n/a |
| Float | 6.40M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.66 |
| PB Ratio | 1.57 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -12.77 |
| EV / Sales | 2.26 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -12.70 |
Financial Position
The company has a current ratio of 1.08, with a Debt / Equity ratio of 0.31.
| Current Ratio | 1.08 |
| Quick Ratio | 0.47 |
| Debt / Equity | 0.31 |
| Debt / EBITDA | n/a |
| Debt / FCF | -2.19 |
| Interest Coverage | -13.26 |
Financial Efficiency
Return on equity (ROE) is -14.74% and return on invested capital (ROIC) is -8.61%.
| Return on Equity (ROE) | -14.74% |
| Return on Assets (ROA) | -7.58% |
| Return on Capital (ROIC) | -8.61% |
| Revenue Per Employee | 7,117 |
| Profits Per Employee | -1,259 |
| Employee Count | 1,096 |
| Asset Turnover | 0.51 |
| Inventory Turnover | 1.98 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +287.50% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +287.50% |
| 50-Day Moving Average | 0.16 |
| 200-Day Moving Average | 0.11 |
| Relative Strength Index (RSI) | 84.49 |
| Average Volume (20 Days) | 13,915 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Pharmesis International had revenue of SGD 7.80 million and -1.38 million in losses. Loss per share was -0.05.
| Revenue | 7.80M |
| Gross Profit | 2.33M |
| Operating Income | -1.85M |
| Pretax Income | -1.32M |
| Net Income | -1.38M |
| EBITDA | -1.63M |
| EBIT | -1.85M |
| Loss Per Share | -0.05 |
Balance Sheet
The company has 642,277 in cash and 3.05 million in debt, giving a net cash position of -2.40 million or -0.08 per share.
| Cash & Cash Equivalents | 642,277 |
| Total Debt | 3.05M |
| Net Cash | -2.40M |
| Net Cash Per Share | -0.08 |
| Equity (Book Value) | 9.85M |
| Book Value Per Share | 0.30 |
| Working Capital | 362,832 |
Cash Flow
In the last 12 months, operating cash flow was -1.36 million and capital expenditures -31,340, giving a free cash flow of -1.39 million.
| Operating Cash Flow | -1.36M |
| Capital Expenditures | -31,340 |
| Free Cash Flow | -1.39M |
| FCF Per Share | -0.04 |
Margins
Gross margin is 29.82%, with operating and profit margins of -23.69% and -17.69%.
| Gross Margin | 29.82% |
| Operating Margin | -23.69% |
| Pretax Margin | -16.86% |
| Profit Margin | -17.69% |
| EBITDA Margin | -20.85% |
| EBIT Margin | -23.69% |
| FCF Margin | -17.80% |
Dividends & Yields
Pharmesis International does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -15.38% |
| Shareholder Yield | -15.38% |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Stock Splits
The last stock split was on August 27, 2015. It was a reverse split with a ratio of 0.1.
| Last Split Date | Aug 27, 2015 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
Pharmesis International has an Altman Z-Score of -0.01. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.01 |
| Piotroski F-Score | n/a |